CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16

描述：（申请人的描述）作为一名学生在医学博士-博士 在阿尔伯特·爱因斯坦医学院的项目中，中川博士研究了 小鼠主要组织相容性复合物结构与功能关系 就其免疫学和生理学特性而言。 后 完成了一个住院医师计划，在实验室医学大学 在加州的旧金山弗朗西斯科，她开始了一项研究， 研究人类乳头瘤病毒16型的细胞介导免疫的项目 (HPV 16）其是宫颈发育不良和癌症的病原体。 数据 迄今为止收集的，使用T细胞增殖测定以及 细胞毒性淋巴细胞试验，支持她的工作假设， 细胞介导的对HPV的免疫有助于其消除， 防止相关疾病的发展。 实验 本申请中提出的建议与正在进行的纵向研究嵌套 其中HPV 16感染的女性没有发展成高级别， 测试上皮内病变的细胞毒性T淋巴细胞应答， HPV 16致癌蛋白，E6和E7。 该项目的具体目标是 为了表征负责抗HPV活性的淋巴细胞亚群， 为了消除背景活性，探索替代方法， 刺激，并制定一项协议，执行细胞毒性T淋巴细胞 使用T细胞系代替大量培养物进行测定。 最后一个目标将给予 为今后HPV 16免疫优势表位的鉴定提供了一种新的工具。 的 该项目的长期目标是开发有效的疫苗， 免疫疗法用于预防和治疗宫颈癌。 博士中川的长期职业目标是继续研究HPV 免疫学作为一个独立的研究者。 她认为这将是最好的 通过成为一名学术医疗中心的教员来完成 在那里她还将作为一名实验室医生承担临床责任 医生。 加州大学旧金山弗朗西斯科， 学术医疗机构与许多杰出的科学家，提供了一个 良好的环境，以发展技能，并进一步她的专业知识， 场来实现自己的目标。

DESCRIPTION: (Applicant's Description) As a student in an M.D.-Ph.D. program at Albert Einstein College of Medicine, Dr. Nakagawa studied the structure function relationships of murine Major Histocompatibility Complex in terms of its immunological and physiological properties. After completing a residency program in laboratory medicine at the University of California at San Francisco, where she still is, she began a research project studying cell-mediated immunity to Human Papilloma Virus type 16 (HPV 16) which is a causative agent of cervical dysplasia and cancer. Data collected thus far, using a T cell proliferative assay as well as a cytotoxic lymphocyte assay, support her working hypothesis that cell-mediated immunity to HPV is instrumental in its elimination and thus is protected against the development of associated diseases. The experiments proposed in this application are nested with an ongoing longitudinal study in which HPV 16 infected women who have not developed high grade intraepithelial lesions are tested for cytotoxic T lymphocyte responses to HPV 16 oncogenic proteins, E6 and E7. The specific aims of this project are to characterize the lymphocyte subset(s) responsible for anti-HPV activity, to eliminate background activity, to explore alternative methods of in vitro stimulation, and to develop a protocol to perform cytotoxic T lymphocyte assay using T cell lines instead of bulk cultures. The last aim will give us a tool to identify immunodominant epitopes of HPV 16 in the future. The long-term goal of this project is to develop effective vaccines and immunotherapy for prevention and treatment of cervical cancer. Dr. Nakagawa's long-term career goal is to continue research in HPV immunology as an independent investigator. She envisions this will be best accomplished by becoming a faculty member at an academic medical center where she will also have clinical responsibilities as a laboratory medicine physician. The University of California at San Francisco, which is a major academic medical institution with many distinguished scientists, offers an excellent environment to develop skills and further her expertise in the field to accomplish her goals.